TITLE

Teva, Active Down Following Laquinimod Phase III Miss

AUTHOR(S)
Wall, Tom
PUB. DATE
August 2011
SOURCE
BioWorld Today;8/2/2011, Vol. 22 Issue 148, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the decline in stocks of pharmaceutical companies Active Biotech AB and Teva Pharmaceutical Industries Ltd. It states that the decline came as a result of the announcement that laquinimod, an oral multiple sclerosis drug, failed to decrease the annualized relapse rate in its Phase III Bravo Trial. It discusses the implications of the Bravo results, with which experts consider laquinimod as unapprovable and beneath the BG-12 drug.
ACCESSION #
63875100

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics